AUA 2017: Relationship Between Quality of Life and Overall Survival in Metastatic Castration-Resistant Prostate cancer patients in ALSYMPCA: Analysis by Prior Docetaxel Subgroup
Boston, MA (UroToday.com) Dr. Shore presented on the relationship between quality of live and overall survival in metastatic castrate-resistant prostate cancer patients with Radium-223 administration analyzed by prior docetaxel. Using the functional assessment of cancer therapy-prostate (FACT-P) they were able to create a time dependent model for change in health-related quality of life scores. Significant associations between overall survival and the FACT-P scores were observed regardless of previous docetaxel treatment. They found that for every 10 point improvement in FACT-P scores from baseline they saw an associated 18-21% improvement in decreased risk of death.
Health-related quality of life is an important measure in metastatic castrate resistant prostate cancer patients. For patients with a poor health related quality of life there is an association with worse overall survival in patients receiving Radium-223. The recognition of health-related quality of life is an important endpoint for these patients receiving Radium-223 and can have a significant impact on overall survival.
Presented By: Neal D. Shore, MD, FACS
Written By: Janet Baack Kukreja (@janetkukreja), MD, MPH, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX, Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Department of Urology, UT MD Anderson Cancer Center, Houston TX
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA